<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619409</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00039232</org_study_id>
    <nct_id>NCT02619409</nct_id>
  </id_info>
  <brief_title>Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash</brief_title>
  <official_title>Evaluation of the Duration of Bupivacaine Spinal Block as the Primary Anesthetic for Orthopedic Procedures With and Without Epinephrine Wash</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bupivacaine spinal is commonly performed as the primary anesthetic for orthopedic procedures.
      In some cases the duration of the block is inadequate. An epinephrine wash is sometimes
      performed to prolong the duration of the block. The epinephrine wash may prolong the duration
      of the block, and if it does, to what extent?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Sensory Block</measure>
    <time_frame>four hours post opervatively</time_frame>
    <description>Duration of the sensory block at the T12 dermatome will be assessed in the post operative phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Motor Block</measure>
    <time_frame>four hours post operatively</time_frame>
    <description>(hip felxion) of the non operative leg</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Arthropathy of Hip</condition>
  <condition>Arthropathy of Knee</condition>
  <arm_group>
    <arm_group_label>Bupivacaine Only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI25 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI50 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI75 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI100 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Only</intervention_name>
    <description>The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.</description>
    <arm_group_label>Bupivacaine Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI25</intervention_name>
    <description>The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.</description>
    <arm_group_label>EPI25 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI50 group</intervention_name>
    <description>The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc</description>
    <arm_group_label>EPI50 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI75 group</intervention_name>
    <description>The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.</description>
    <arm_group_label>EPI75 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI100 group</intervention_name>
    <description>The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.</description>
    <arm_group_label>EPI100 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Patients scheduled for total hip or knee replacement

        Exclusion Criteria:

          -  Patients taking anticoagulation

          -  Infection at or near the intended needle insertion site

          -  Patients with sacral decubitus ulcer at or near the intended needle insertion site
             aortic stenosis

          -  Complex spine anatomy

          -  ASA class greater than III

          -  Failed SAB as determined by the staff anesthesiologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Eric Bolin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 28, 2018</submitted>
    <returned>March 27, 2018</returned>
    <submitted>April 11, 2018</submitted>
    <returned>May 11, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

